Major Milestones

2021
10Month
RECOMBINANT POLYPEPTIDES AND NUCLEIC ACID MOLECULES, COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from China National Intellectual Property Administration.
9Month
Additional investment in Osteopharma, Inc., Japan increasing the shareholding ratio to 46.73%.


4Month
April 21, 2021. BioGend submitted the application for importing permit of 「“RevoCart” One-Step Autologous Cartilage Repair System」to China National Medical Products Administration.
2Month
“RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from USPTO.
1Month
BioGend acquired self-paid price for RevoCart one-step autologous cartilage repair system.
2020
12Month
BioGend Therapeutics Co., Ltd. (stock code: 6733) held a performance presentation before stock listing on December 22, 2020
11Month
RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from Taiwan Intellectual Property Office (TIPO).
“RECOMBINANT POLYPEPTIDES AND NUCLEIC ACID MOLECULES, COMPOSITIONS AND METHODS OF MAKING AND USES THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from European Patent Office (EPO).
10Month
“RECOMBINANT POLYPEPTIDES AND NUCLEIC ACID MOLECULES, COMPOSITIONS AND METHODS OF MAKING AND USES THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from USPTO.
4Month
BiG009 “RevoCart One-step Autologous Cartilage Repair System” has received the premarket approval (Certificate No. 006689) from the TFDA.
2019
12Month
BiG009 RevoCart Clinical Evaluation Report was accepted by the FDA.
11Month
Obtained the“Scientific and Technological Business Opinion”letter issued by Bureau of Industry, Ministry of Economic Affairs.
9Month
Additional investment in Osteopharma, Inc., Japan increasing the share holding from 16 to 43%.
8Month
"RECOMBINANT POLYPEPTIDES AND NUCLEIC ACID MOLECULES, COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from Taiwan Intellectual Property Office (TIPO).
7Month
1.BiG-009, RevoCart has completed the data analysis of the pivotal trial indicating the outcome measures were met.
2.The contract manufacturer of BiG-009, RevoCart has passed the GMP inspection and accreditation by the TFDA.
6Month
The major protein used in BiG-001 and BiG-006 to stimulate bone regeneration received a patentable ruling related to active ingredients from the Taiwan Intellectual Property Office.
Completed registration at the TPEx Emerging Stock Board
4Month
Applied to TPEx Emerging Stock Board to issue the stock public offering, effective April 3, 2019.
2Month
Issued 12,000,000 new shares at TWD 10 per share for employee purchase, increasing the paid-in capital to 820 million TWD.
2018
10Month
Issued 14,289,300 new shares at TWD 30 per share increasing the paid-in capital to 700 million TWD.
6Month
BiG-001 received the conditional approval from the TFDA for an IDE clinical study.
4Month
BiG-009, RevoCart completed the enrollment of the last patient required in the pivotal clinical trial.
3Month
Completed merge with Exactech Taiwan; issued 5,710,700 new shares at TWD 10 per share, increasing the paid-in capital to 557,107,000 TWD
2017
12Month
Merged with Exactech Taiwan with a stock-for-stock transaction, and the merging date was December 31, 2017.
10Month
BiG-001, Osteoinductive Bone Graft for Fracture Fixation, and BiG-006, Osteoinductive Bone Graft for Spinal Fusion, met the qualification requirement in the Act For The Development Of Biotech And New Pharmaceuticals Industry.
8Month
Made a strategic investment in Excactech Taiwan and obtained 81% of shares.
5Month
Completed a new round of fundraising by issuing 25 million shares at TWD 10 per share, increasing the paid-in capital to 500 million TWD.
2016
7Month
Obtained the right to the osteoinductive factor from Osteopharma, Inc., Japan; made a strategic investment in exchange of 16% of shares
BioGend incorporated with the capital of 250 million TWD